OCUL Ocular Therapeutix, Inc.

8.70
+0  (4%)
Previous Close 8.40
Open 8.44
Price To book 4.04
Market Cap 250.18M
Shares 28,756,000
Volume 380,125
Short Ratio 5.24
Av. Daily Volume 1,044,360

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 14, 2016. Primary endpoints met.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016
DEXTENZA
Allergic conjunctivitis
Phase 3 initiated October 2016. Data due 1H 2018.
OTX-TP
Glaucoma and ocular hypertension
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmitted, PDUFA date July 19, 2017.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease

Latest News

  1. ETFs with exposure to Ocular Therapeutix, Inc. : April 10, 2017
  2. Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer
  3. ETFs with exposure to Ocular Therapeutix, Inc. : March 27, 2017
  4. Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  5. Positive Results Reported For Ocular Therapeutix Inc (OCUL) Dextenza Following Phase III Study
  6. Why Ocular Therapeutix Inc Saw its Share Price Jump Today
  7. Ocular's Dextenza Reports Positive Study Results
  8. After setback, Bedford eye care biotech has its sights set on FDA approval
  9. New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract Surgery
  10. Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  11. Edited Transcript of OCUL earnings conference call or presentation 10-Mar-17 1:30pm GMT
  12. Ocular Therapeutix reports 4Q loss
  13. Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results
  14. Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results
  15. Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS)
  16. Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for the Treatment of Ocular Pain
  17. Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery
  18. Why Ocular Therapeutix Inc Jumped Higher Today
  19. Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences
  20. ETFs with exposure to Ocular Therapeutix, Inc. : January 25, 2017